HTL Biotechnology inaugurates a new production line dedicated to sterile Hyaluronic Acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
Press releases
February 28, 2022
Montagu as new investor
February 28, 2022
HTL announces that Montagu, a leading private equity firm, has acquired a majority stake of HTL previously held by Bridgepoint. The other minority shareholders, Naxicap and Téthys Invest, will keep their shares in the company.
The arrival of this new shareholder symbolizes the international success of a company that has become the world leader in the development and production of pharmaceutical grade biopolymers.
To see our most recent news,
follow us on LinkedIn
Read more
news from us
-
Articles December 12, 2025HTL Biotechnology joins the Choiseul Conquérants 2025 ranking
HTL Biotechnology is recognized for the second consecutive year among France’s most dynamic and innovative mid-sized companies.
-
Articles October 29, 2025HTL Inside Webinar: a success that boosts our visibility in Asia
On October 28, 2025, HTL Biotechnology hosted its first-ever webinar, “Shaping the Future of Aesthetic Medicine with Premium Biopolymers,” a key initiative to strengthen our presence in Asia and promote the “Feel the Difference with HTL Inside” positioning among major players in aesthetic medicine.
-
Articles October 9, 2025HTL Biotechnology rallies for Pink October 2025
This October, HTL Biotechnology turned pink to support breast cancer prevention.